Tim Boire is the president and CEO of VenoStent, a medical device startup that’s designing a unique material for hemodialysis patients. The company just closed its series A at $16 million dollars and is gearing up for a 200-patient clinical trial. Tim shares how he’s grown his company since moving it to Houston in 2018 to tap into the local innovation ecosystem. He also outlines where VenoStent is headed, with its expected product launch in 2026.